Rocket Pharmaceuticals (RCKT) Cash from Operations (2014 - 2026)
Rocket Pharmaceuticals (RCKT) reported Cash from Operations of 45394000.0 for Q1 2026, up 18.63% on a YoY basis from 38263851.27 in Q1 2025, and down 30.29% sequentially from 34840000.0 in Q4 2025.
Rocket Pharmaceuticals (RCKT) Cash from Operations (2014 - 2026) Analysis & Trends
Rocket Pharmaceuticals (RCKT) has 13 years of Cash from Operations data on file, last reported at 45394000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 18.63% year-over-year to 45394000.0; the trailing twelve-month figure through Mar 2026 stood at 179618000.0 (up 13.92% YoY), and the FY2025 full-year result was 190014000.0, up 9.4% from the prior year.
- Cash from Operations retreated to 45394000.0 in Q1 2026, from 34840000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 29339000.0 in Q4 2023 to a low of 57560000.0 in Q1 2023.
- A 5-year average of 48128823.53 and a median of 50420000.0 in 2025 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations tumbled 81.06% in 2022 and jumped 47.63% in 2023, its largest moves.
- Tracing RCKT's Cash from Operations over 5 years: stood at 56021000.0 in 2022, then jumped by 47.63% to 29339000.0 in 2023, then sank by 60.0% to 46942000.0 in 2024, then advanced by 25.78% to 34840000.0 in 2025, then tumbled by 30.29% to 45394000.0 in 2026.
- Business Quant data shows RCKT's Cash from Operations at 45394000.0 in Q1 2026, 34840000.0 in Q4 2025, and 50420000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Rocket Pharmaceuticals | 357.93 Mn | 357.93 Mn | - | -45.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.39 Mn |
| Mar 31, 2026 | -45.39 Mn |
| Dec 31, 2025 | -34.84 Mn |
| Dec 31, 2025 | -34.84 Mn |
| Sep 30, 2025 | -50.42 Mn |
| Sep 30, 2025 | -50.42 Mn |
| Jun 30, 2025 | -48.96 Mn |
| Jun 30, 2025 | -48.96 Mn |
| Mar 31, 2025 | -55.79 Mn |
| Mar 31, 2025 | -55.79 Mn |
| Dec 31, 2024 | -46.94 Mn |
| Dec 31, 2024 | -46.94 Mn |
| Sep 30, 2024 | -52.10 Mn |
| Sep 30, 2024 | -52.10 Mn |
| Jun 30, 2024 | -53.82 Mn |
| Jun 30, 2024 | -53.82 Mn |
| Mar 31, 2024 | -56.86 Mn |
| Mar 31, 2024 | -56.86 Mn |
| Dec 31, 2023 | -29.34 Mn |
| Dec 31, 2023 | -29.34 Mn |